fashion -WSS

fashion

author：explore 2025-08-12 11:28:04 - browse：9978

KalVista Pharmaceuticals said Tuesday that its oral, on-demand treatment for the swelling “attacks” commonly experienced by patients with a genetic condition called hereditary angioedema achieved the goals of a Phase 3 clinical trial.

Based on the study results, the company plans to submit a marketing application to the Food and Drug Administration by the middle of the year. Regulatory filings in Europe and Japan will be completed later in the year.

In the Phase 3 study involving 136 participants, a low and high dose of Kalvista’s drug, called sebetralstat, showed a median time to the beginning of symptom relief of 1.6 hours and 1.8 hours, respectively, compared to 6.7 hours for a placebo. The result was statistically significant and achieved the study’s main efficacy goal.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Pence says 'crackpot lawyers' told Trump what he wanted to hear

WSS

Pence says 'crackpot lawyers' told Trump what he wanted to hear

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Mega Millions pot grows to $1.25 billion after no winner

Takeda, Janssen join wearable maker to measure scratching

New safety details link Apellis eye drug to rare cases of blindness

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

focus

fashion

focus

Bright Health sells Medicare Advantage business to Molina

New safety details link Apellis eye drug to rare cases of blindness

Virginia high school admissions case could be legal follow

‘Oppenheimer’ and the risks of AI in health care

23andMe had bad news about my health. I wish a person had delivered it

National panel will explore requiring free Covid tests

Heart attack and stroke risk calculators need revising

BIO selects John Crowley as new CEO

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

The EPA's new lead rule: How one expert crunched the numbers

hotspot

BIO selects John Crowley as new CEO

Despite FDA concern, risk that CAR

Diagnostic tests are hitting their mathematical limits

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

FDA investigates CAR

Vertex non

focus

Wikipedia

leisure time

hotspot